Pragmatic Randomized Trial of Calcitriol in Patients with Chronic Kidney Disease
骨化三醇治疗慢性肾病患者的实用随机试验
基本信息
- 批准号:8793064
- 负责人:
- 金额:$ 56.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-19 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAlgorithmsAtherosclerosisBiological MarkersCalcifediolCalcitriolCardiovascular DiseasesCardiovascular systemCaringCell physiologyCessation of lifeCholecalciferolChronic Kidney FailureClinicalClinical TrialsCommitComplicationComprehensive Health CareDataDietDiseaseElectronicsEligibility DeterminationEnd stage renal failureEnrollmentEventExperimental Animal ModelFractureGlomerular Filtration RateHealthHealthcare SystemsHeart failureHormonalHormonesHospitalizationImmuneIncidenceIndividualIntegrated Health Care SystemsInterventionIntervention StudiesInvestigationKidneyLaboratoriesLeadLeft Ventricular HypertrophyMalignant NeoplasmsMeasuresMonitorMorbidity - disease rateMyocardial InfarctionObservational StudyOral cavityOutcomeOutcome StudyParathyroid glandParticipantPatientsPharmaceutical PreparationsPhasePopulationPrevalenceProductionProtocols documentationRandomizedRandomized Clinical TrialsRecruitment ActivityRelative (related person)Renin-Angiotensin SystemResearchResearch InfrastructureResidual stateResourcesRiskSafetySecondary HyperparathyroidismSiteSkinStrokeSurrogate EndpointTestingTherapeutic AgentsUniversitiesVisitVitamin DWashingtonabstractingacute coronary syndromeadjudicationcardiovascular disorder riskcardiovascular risk factorclinical careclinically relevantcohortcostdesignfallshigh riskimprovedmortalitymultidisciplinaryprimary outcomerandomized trialsecondary outcometreatment as usual
项目摘要
DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) is common and is associated with substantial morbidity and mortality, which is largely due to an increased incidence of cardiovascular diseases. Calcitriol (1,25-dihydroxyvitamin D3, the active vitamin D hormone) is a particularly promising treatment to reduce cardiovascular morbidity and mortality in CKD. The kidneys are the major site of calcitriol production, and circulating calcitriol concentrations fall dramatically in CKD, even when standard vitamin D supplements are administered. Provocative cardioprotective actions of calcitriol have been demonstrated in animal-experimental models, and observational studies of people with CKD consistently demonstrate associations of calcitriol use with reduced mortality. However, no clinical trial has tested the effects of calcitriol on clinical outcomes. The objective of the proposed research is to
determine, in a randomized clinical trial, whether calcitriol use (0.25 mcg by mouth daily) reduces the risk of cardiovascular disease events among people with CKD (estimated glomerular filtration rate 20-59 mL/min/1.73m2). During the UH2 phase of our study, we aim to demonstrate the feasibility of integrating a well-designed pragmatic clinical trial of calcitriol ito the clinical care infrastructure of Group Health Cooperative, a large integrated health care system. During the UH3 phase of our study, the study aim is to test the effect of calcitriol plus usual care, compared with usual care alone, on the occurrence of clinically relevant cardiovascular outcomes (primary composite outcome of myocardial infarction, acute coronary syndrome, stroke, hospitalized heart failure, or cardiovascular death) among 4,370 Group Health patients with CKD. Secondary outcomes will include components of the primary composite outcome and progression of CKD to end stage renal disease. We have assembled a multidisciplinary team of collaborators from Group Health and the University of Washington to develop and conduct this pragmatic clinical trial. The study will maximize efficiency, economy, and external validity by applying minimal eligibility criteria and by utilizing an extensive array f electronic resources to identify participants, deliver and monitor the study intervention, and ascertain study outcomes. Individual-level randomization, standardized protocols to promote retention and adherence, and rigorous ascertainment of study outcomes will enhance internal validity.
描述(由申请人提供):慢性肾脏疾病(CKD)很常见,并与大量发病率和死亡率相关,这主要是由于心血管疾病的发病率增加。骨化三醇(1,25-二羟基维生素D3,活性维生素D激素)是一种特别有前途的治疗方法,可降低CKD的心血管发病率和死亡率。肾脏是骨化三醇产生的主要部位,即使给予标准维生素D补充剂,CKD患者的循环骨化三醇浓度也会急剧下降。骨化三醇的激发性心脏保护作用已在动物实验模型中得到证实,对CKD患者的观察性研究一致表明骨化三醇的使用与死亡率降低有关。然而,没有临床试验测试骨化三醇对临床结果的影响。拟议研究的目的是
在一项随机临床试验中,确定骨化三醇的使用(每日口服0.25 mcg)是否可降低CKD患者(估计肾小球滤过率20-59 mL/min/1.73m2)发生心血管疾病事件的风险。在我们研究的UH 2阶段,我们的目标是证明将精心设计的实用的骨化三醇临床试验整合到团体健康合作社(一个大型综合医疗保健系统)的临床护理基础设施的可行性。在我们研究的UH 3阶段,研究的目的是在4,370例健康组CKD患者中测试骨化三醇加常规护理与单独常规护理相比对临床相关心血管结局(心肌梗死、急性冠状动脉综合征、卒中、住院心力衰竭或心血管死亡的主要复合结局)发生率的影响。次要结局将包括主要复合结局的组成部分和CKD进展为终末期肾病。我们已经组建了一个多学科的团队,由来自Group Health和华盛顿大学的合作者组成,以开发和进行这项实用的临床试验。本研究将通过应用最低合格性标准和利用广泛的电子资源来识别受试者、提供和监测研究干预并确定研究结局,从而最大限度地提高效率、经济性和外部效度。个体水平的随机化、促进保留和依从性的标准化方案以及对研究结果的严格确认将增强内部效度。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DELIA SCHOLES其他文献
DELIA SCHOLES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DELIA SCHOLES', 18)}}的其他基金
Oral Contraceptive Use and Fractures Around the Menopausal Transition
口服避孕药的使用和绝经过渡期的骨折
- 批准号:
7848107 - 财政年份:2008
- 资助金额:
$ 56.28万 - 项目类别:
Oral Contraceptive Use and Fractures Around the Menopausal Transition
口服避孕药的使用和绝经过渡期的骨折
- 批准号:
8078010 - 财政年份:2008
- 资助金额:
$ 56.28万 - 项目类别:
Oral Contraceptive Use and Fractures Around the Menopausal Transition
口服避孕药的使用和绝经过渡期的骨折
- 批准号:
7523951 - 财政年份:2008
- 资助金额:
$ 56.28万 - 项目类别:
Oral Contraceptive Use and Fractures Around the Menopausal Transition
口服避孕药的使用和绝经过渡期的骨折
- 批准号:
8287606 - 财政年份:2008
- 资助金额:
$ 56.28万 - 项目类别:
Oral Contraceptive Use and Fractures Around the Menopausal Transition
口服避孕药的使用和绝经过渡期的骨折
- 批准号:
7677912 - 财政年份:2008
- 资助金额:
$ 56.28万 - 项目类别:
Ectopic Pregnancy: Assessing Long-Term Trends in Rates and Risk Factors
宫外孕:评估发生率和风险因素的长期趋势
- 批准号:
7208541 - 财政年份:2007
- 资助金额:
$ 56.28万 - 项目类别:
PROMOTING ADOPTION OF SAFER SEX PRACTICES IN YOUNG WOMEN
促进年轻女性采取更安全的性行为
- 批准号:
2883408 - 财政年份:1998
- 资助金额:
$ 56.28万 - 项目类别:
PROMOTING ADOPTION OF SAFER SEX PRACTICES IN YOUNG WOMEN
促进年轻女性采取更安全的性行为
- 批准号:
2649837 - 财政年份:1998
- 资助金额:
$ 56.28万 - 项目类别:
PROMOTING ADOPTION OF SAFER SEX PRACTICES IN YOUNG WOMEN
促进年轻女性采取更安全的性行为
- 批准号:
6165373 - 财政年份:1998
- 资助金额:
$ 56.28万 - 项目类别:
相似海外基金
CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
- 批准号:
2337776 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
- 批准号:
2338816 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
- 批准号:
2338846 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
- 批准号:
2348261 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
- 批准号:
2348346 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
- 批准号:
2348457 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
- 批准号:
2404989 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
- 批准号:
2339310 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
- 批准号:
2339669 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Continuing Grant
DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
- 批准号:
EP/Y029089/1 - 财政年份:2024
- 资助金额:
$ 56.28万 - 项目类别:
Research Grant